Coloplast (COLO) CMD 2024 summary

Strategic direction and growth initiatives

• Focus on sustainable growth leadership through Strive25, emphasizing innovation, efficiency, and M&A to build growth platforms, particularly in the US and China.

• Four growth platforms established: Chronic Care, Advanced Wound Care, Interventional Urology, and Voice & Respiratory Care, each with strong long-term potential in reimbursed niche markets with differentiated technology.

• M&A activity includes Atos Medical, Kerecis, and Intibia, supporting portfolio expansion and new market entry; integration of Atos Medical expected to yield up to 100m DKK in synergies.

• Investments in direct-to-consumer, digital, and commercial expansion, with selective investments in emerging markets and a focus on the US.

• Growth driven by innovation, share gains in the US, sustained double-digit growth in emerging markets, and successful integration of recent acquisitions.

Financial performance and guidance

• Achieved 8% organic and 9% reported revenue growth in H1 2023/24, with a 27% EBIT margin; full-year guidance confirmed at 8% organic, 10-11% reported revenue growth, and 27-28% EBIT margin.

• Long-term guidance targets 8-10% organic growth per annum and EBIT margin above 30% beyond 2024/25, with temporary margin dilution from Kerecis.

• Dividend policy targets a 60-80% payout ratio of net profit, with bi-annual payouts and consistent share buybacks.

• Expected improvement in net working capital and deleveraging to below 2x EBITDA in 2024/25.

• Margin improvement expected as input costs, energy, and wage inflation ease, supported by procurement, cost discipline, and ramp-up in Costa Rica.

Innovation, product launches, and M&A

• Rolling out the largest product roadmap in company history, including Luja (catheter with Micro-hole Zone Technology), Heylo (digital leakage notification system), and SenSura Mio black bags.

• Continued launches in existing categories, such as Peristeen Light for bowel care, supporting consistent double-digit growth in these segments.

• Three major M&A investments: Atos Medical (expected 8-10% growth, mid-30s EBITDA margin), Kerecis (30% CAGR, 20% EBIT margin by 2025/26), and Tibial/Intibia (entry into overactive bladder, launch expected 2025-26).

• Ongoing portfolio development with generation 1-3 product extensions and entry into new indications for wound care.

• Sustainability and operational efficiency prioritized, including new factories, procurement programs, and transition to green energy.